Karnataka challenges Snapdeal’s safe-harbour defence over online sale of ED pills

Karnataka has moved the Supreme Court against safe-harbour protection for Snapdeal in a case involving alleged unlicensed online sales of prescription erectile-dysfunction drugs. The outcome could raise compliance and liability exposure for marketplaces and e-pharmacy platforms.

— Source publishedTue, 21 Jul, 2026, 18:46 IST·First seen Tue, 21 Jul, 2026, 19:18 IST·Source Medianama

What happened

Karnataka has challenged Snapdeal's safe-harbour protection before the Supreme Court over alleged unlicensed online sale of prescription erectile-dysfunction

Key facts

  • Suhagra-100
  • Section 79
  • Drugs and Cosmetics Act, 1940
  • Drugs and Cosmetics Rules, 1945
  • 2021
  • August 10, 2026

Why this matters

Acquirers and partners should diligence prescription-drug workflows, seller credentials and historical enforcement exposure, since weak controls could create post-deal liability if safe harbour is curtailed.

What to watch

  • Supreme Court notices, interim observations, and whether the bench frames the issue as intermediary liability, drug-sale licensing, or platform knowledge and control.
  • Any judicial emphasis on platform functions such as inventory possession, fulfilment, payments, advertising, algorithmic promotion, or seller verification.
  • Drug regulator advisories or coordinated state enforcement targeting online prescription-drug listings.
  • Changes to marketplace policies requiring prescriptions or drug-licence documentation for health and wellness categories.
  • A rise in delistings, seller suspensions, consumer complaints, or competing e-pharmacy marketing around verified prescriptions.
  • Marketplaces will review and potentially delist prescription medicines, sexual-wellness products with drug claims, controlled substances, and sellers lacking verifiable drug licences.
  • Large e-pharmacies and horizontal marketplaces will invest in e-prescription capture, pharmacist review, geo-specific licence validation, seller KYC, and repeat-offender monitoring.
  • Platforms may revise merchant agreements to shift regulatory warranties, indemnities, and record-keeping obligations onto sellers while increasing seller onboarding friction.
  • State drug-control authorities may use the case to seek transaction, seller, and fulfilment data from marketplaces and pursue enforcement against logistics partners and payment intermediaries.
  • Consumer demand may migrate toward licensed e-pharmacies, offline chemists, and direct-to-consumer channels if broad marketplaces restrict access to prescription products.

Also reported by